Every material Form 8-K TriSalus Life Sciences, Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TriSalus Life Sciences said it received FDA 510(k) clearance for its TriNav Advance device, an addition to its Pressure-Enabled Drug Delivery portfolio. The company expects to begin commercialization with the clearance and plans a limited market release over the coming weeks.
FDA 510(k) clearance announced September 22, 2026 for TriNav Advance
Device can be used in telescoping configuration with a compatible microcatheter to reach smaller, distal vessels, or in high-flow configuration without one
Company intends to initiate a limited market release over the coming weeks
TriSalus Life Sciences reported second quarter 2026 revenue of $11.4 million, up 1.7% from a year earlier, while its operating loss widened to $9.8 million from $7.3 million as sales and marketing spending rose. The company maintained its full-year 2026 revenue guidance of $54 million to $57 million, which it said represents growth of 19% to 26% over 2025.
Q2 2026 revenue was $11.4 million, up 1.7% from $11.2 million in Q2 2025; gross margin rose to 86.8% from 83.9%.
Sales and marketing expense rose to $11.4 million from $7.2 million, driving the operating loss to $9.8 million.
Net loss attributable to common stockholders was $9.2 million, or $0.16 per share, compared with $9.0 million, or $0.27 per share, a year earlier.
Full-year 2026 revenue guidance of $54 million to $57 million was maintained; cash and cash equivalents were $46.3 million at June 30, 2026.
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million, down 2.9% from a year earlier, and revised its 2026 revenue guidance to $54 million to $57 million. Net income was $1.5 million, or $0.03 per share, but that result reflected $11.3 million of non-cash derivative gains, while the operating loss widened, so shareholders face a mixed picture.
Q1 2026 revenue was $8.9 million, down 2.9% from $9.2 million in Q1 2025, which the company attributed mainly to its commercial expansion.
Operating loss widened to $8.4 million from $7.3 million, and adjusted EBITDA loss widened to $5.8 million from $5.5 million.
Net income attributable to common stockholders was $1.5 million, or $0.03 per share, versus a net loss of $11.1 million, or $(0.39) per share, a year earlier; the company cited $11.3 million of non-cash fair value gains on derivatives.
2026 revenue guidance was revised to $54 million to $57 million, citing lower Q1 revenue and delayed FDA clearance timing for TriNav Advance; cash totaled $56.6 million on March 31, 2026, after a $46.0 million gross equity raise.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TriSalus Life Sciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →